ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics. ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells are analyzed by whole genome sequencing. ARCEDI launched EVITA TEST COMPLETE, world's first and only cell-based NIPT which is currently being offered via 23 clinics in Denmark.
Looking for a particular ARCEDI Biotech employee's phone or email?
The ARCEDI Biotech annual revenue was $3 million in 2026.
Mads Dalsgaard is the Chief Executive Officer at ARCEDI Biotech of ARCEDI Biotech.
18 people are employed at ARCEDI Biotech.
The NAICS codes for ARCEDI Biotech are [54171, 541, 54, 5417, 541713].
The SIC codes for ARCEDI Biotech are [873, 87].